SML3213
Lobaplatin
≥98% (NMR)
别名:
Cis-[trans-1,2-cyclobutanebis(methylamine)-N,N′]-[(2S)-lactate-O1,O2)-platinum (II), D 19466, D-19466, D19466, [rel-(1R,2R)-1,2-cyclobutanedimethanamine-κN,kN′][(2S)-2-(hydroxy-kO)propanoato(2-)-kO]-, (SP-4-3)-platinum, trans-1,2-Cyclobutanedimethanamine, platinum complex
产品名称
Lobaplatin, ≥98% (NMR)
InChI
1S/C6H12N2.C3H5O3.Pt/c7-3-5-1-2-6(5)4-8;1-2(4)3(5)6;/h5-8H,1-4H2;2H,1H3,(H,5,6);/q-2;-1;+4/p-1/t;2-;/m.0./s1
InChI key
HADHSETVEMCBPU-TYOUJGAFSA-M
SMILES string
O=C1[O-][Pt+2]2(N[CH2]C3CCC3CN2)[O-]C1C
assay
≥98% (NMR)
form
powder
color
white to beige
solubility
H2O: 2 mg/mL, clear (Warmed)
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Lobaplatin (D-19466) is a third-generation platinum anticancer agent in vitro and in vivo, consisting of ~50:50 mixture of the two trans-1,2-cyclobutanedimethanamine diastereomers in complex with L-lactic acid. Llobaplatin shows antitumor efficacy against various human cancer cancer xenografts and significantly prolongs the survival of mice bearing P388 leukemia (mean life span increase post single i.p. in mg/kg = 46%/4.64 & 77/14.7). Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.
Third-generation platinum anticancer agent in vitro and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hongming Zhang et al.
Frontiers in oncology, 9, 538-538 (2019-08-21)
Platinum-based chemotherapy is recommended as the first-line treatment regimen for patients with advanced non-small-cell lung cancer (NSCLC). Lobaplatin (LBP), a third-generation platinum anti-neoplastic agent, has shown an improved efficacy. This study is aimed to investigate the mechanisms of LBP-induced apoptosis
A Harstrick et al.
Cancer chemotherapy and pharmacology, 33(1), 43-47 (1993-01-01)
Lobaplatin [1,2-diamminomethylcyclobutane-platinum(II) lactate] is a new platinum compound with interesting preclinical activity and apparently no nephro- or neurotoxicity that is currently undergoing clinical phase II studies. Little is known about the cross-resistance between cisplatin and lobaplatin. The activity of this
R Voegeli et al.
Journal of cancer research and clinical oncology, 116(5), 439-442 (1990-01-01)
D-19466, a new platinum complex, was characterized. It showed no nephrotoxic side-effects as determined by the measurement of blood urea. It was cytotoxic in vitro for tumor cells in concentrations comparable to or lower than cytotoxic concentrations of cisplatin. It
Shupei Pan et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 102, 567-574 (2018-03-30)
Radiotherapy is one of the common treatments for esophageal squamous cell carcinoma (ESCC). Yet, local recurrence led by radioresistance is still not solved. Lobaplatin (LBP) is known to have powerful clinical anti-tumor activities in various tumors, but its effect in
Junhui Yu et al.
Cell death & disease, 10(3), 193-193 (2019-02-26)
Pyroptosis, a form of programmed cell death (PCD), has garnered increasing attention as it relates to innate immunity and diseases. However, the involvement of pyroptosis in the mechanism by which lobaplatin acts against colorectal cancer (CRC) is unclear. Our study
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持